Brief: Vir Biotechnology Receives FDA IND Clearance And Fast Track Designation For Tobevibart And Elebsiran For The Treatment Of Chronic Hepatitis Delta Infection
26/06/2024 13:17
June 26 (Reuters) - Vir Biotechnology Inc VIR.O :
* VIR BIOTECHNOLOGY RECEIVES FDA IND CLEARANCE AND FAST
TRACK
DESIGNATION FOR TOBEVIBART AND ELEBSIRAN FOR THE TREATMENT OF
CHRONIC HEPATITIS DELTA INFECTION
* VIR BIOTECHNOLOGY INC - COMPLETE 24-WEEK TREATMENT DATA
EXPECTED
Q4
Source text for Eikon: ID:nBw97tcFYa
Further company coverage: VIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO